BRCA2 germline pathogenic in metastatic PDAC: olaparib maintenance after ≥16 weeks platin...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRCA2-GERMLINE-PDAC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PDAC |
| Sources | SRC-CIVIC SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 |
Actionability Facts
| Biomarker | BIO-BRCA1-BRCA2-GERMLINE |
|---|---|
| Variant | BRCA2 germline pathogenic |
| Disease | DIS-PDAC |
| ESCAT tier | IA |
| Recommended combinations | olaparib monotherapy maintenance after platinum induction (FOLFIRINOX preferred) |
| Evidence summary | BRCA2 germline pathogenic in metastatic PDAC: olaparib maintenance after ≥16 weeks platinum without progression (POLO) → mPFS 7.4 vs 3.8 mo. ESCAT IA / OncoKB Level 1. |
Notes
Cascade testing mandatory. BRCA2 PDAC patients have improved platinum sensitivity overall.
Used By
No reverse references found in the YAML corpus.